Rosetta Genomics’ Patent on Therapeutic Use of miR-34a Upheld by European Patent Office in Opposition Proceedings
April 29 2015 - 8:56AM
Business Wire
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular and other diagnostics,
announces that the European Patent Office (EPO) has upheld the
validity of the Company’s European Patent No. 2126078, following
the oral proceedings in the Opposition Proceedings against
Rosetta's patent held on April 23, 2015 in Munich, Germany.
Since the grant of Rosetta's patent in April 2012, two
opposition requests were filed by anonymous parties. Rosetta was
able to overcome the grounds for revocation presented by the
parties and maintain the patent on the therapeutic use of miR-34a,
which has been proven to have significant effects in cancer
therapy.
The European patent, which claims the use of miR-34a or its
variants for treating p53-negative cancers, covers a core element
of Rosetta Genomics’ microRNA technology in the development of
cancer therapeutics associated with p53-negative cancers, including
lymphoma, breast cancer, ovarian cancer, liver cancer, skin cancer,
certain types of lung cancer, and others. The patent is jointly
owned with Yeda R&D Co. Ltd., the technology transfer company
of the Weizmann Institute of Science in Rehovot, Israel.
“We are gratified that the EPO has upheld these important claims
for the therapeutic use of miR-34a to treat a variety of
p53-negative cancers. This affirms our belief in the validity of
these claims and the groundbreaking nature of our microRNA
technology to serve as a potential treatment for these various
cancer indications,” said Kenneth A. Berlin, President and Chief
Executive Officer of Rosetta Genomics. “The successful examination
and defense of this therapeutic patent highlights that this
invention is seminal for the use of microRNAs in the development of
cancer therapeutics and underscores the importance of the work
performed by our researchers and their co-inventors at the Weizmann
Institute of Science.”
In February 2015, the Company announced receipt of a Notice of
Allowance from the United States Patent and Trademark Office for
U.S. Patent Application No. 14/280,822 (now U.S. Patent No.
9,006,206), a patent claiming the use of miR-34a for the treatment
of p53-associated cancers. This U.S. patent complements the
European patent in that it covers the treatment of any
p53-associated cancer using miR-34a.
About Rosetta Cancer Testing Services
Rosetta Cancer Tests are a series of microRNA-based diagnostic
testing services offered by Rosetta Genomics. The Rosetta Cancer
Origin Test™ can accurately identify the primary tumor type in
primary and metastatic cancer including cancer of unknown or
uncertain primary (CUP). The Rosetta Lung Cancer Test™ accurately
identifies the four main subtypes of lung cancer using small
amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately
classifies the four most common kidney tumors: clear cell renal
cell carcinoma (RCC), papillary RCC, chromophobe RCC and
oncocytoma. Rosetta’s assays are designed to provide objective
diagnostic data. In the U.S. alone, Rosetta Genomics estimates that
200,000 patients a year may benefit from the Rosetta Cancer Origin
Test™, 62,000 from the Rosetta Kidney Cancer Test™ and 222,000
patients from the Rosetta Lung Cancer Test™. The Company’s assays
are offered directly by Rosetta Genomics in the U.S., and through
distributors around the world. In addition to its proprietary
products, the Company markets the Rosetta Genomics PGxOne™ and EGFR
and KRAS tests for Admera Health. With the recent acquisition of
PersonalizeDx, the company now offers a broader menu of molecular
and other assays for lung, bladder, prostate and breast cancer
patients. For more information, please visit
www.rosettagenomics.com. Parties interested in ordering any of
these tests can contact Rosetta Genomics at (215) 382-9000 ext.
309.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based molecular diagnostics. Founded in 2000, Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. PersonalizeDx’s core
FISH, IHC and PCR-based testing capabilities and partnerships in
oncology and urology provide additional content and platforms that
complement the Rosetta offerings. Rosetta’s and PersonalizeDx’s
cancer testing services are commercially available through the
Philadelphia, PA- and Lake Forest, CA-based CAP-accredited,
CLIA-certified labs, respectively.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects, including without
limitation, statements relating to the commercial
potential and patentability of the aforementioned patent, Rosetta's
monetization of said patent, as well as the ability of said patent
to withstand continuous appeals and the possibilities for
Rosetta's expanding its commercial offerings and/or clinical
pipeline, constitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially
from those indicated by these forward-looking statements as a
result of various important factors, including those risks more
fully discussed in the "Risk Factors" section of Rosetta’s Annual
Report on Form 20-F for the year ended December 31, 2014 as
filed with the SEC. In addition, any forward-looking statements
represent Rosetta’s views only as of the date of this release and
should not be relied upon as representing its views as of any
subsequent date. Rosetta does not assume any obligation to update
any forward-looking statements unless required by law.
Rosetta GenomicsKen Berlin, President & CEO(609)
419-9003investors@rosettagenomics.comorInvestor:LHAAnne
Marie Fields(212) 838-3777afields@lhai.comorBruce Voss(310)
691-7100bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Sep 2023 to Sep 2024